Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist with large phase III programmes in type 2 diabetes, obesity, and cardiovascular outcomes. One of the few entries here where the evidence base is genuinely deep.
For Research & Educational Discussion Only. Not Medical Advice
Baseline · Research Archive
A member-supported educational community. Every compound gets a plain-language guide of what the studies actually showed and where the evidence runs out, and every guide opens onto its own forum, so the reference material and the argument about it live in one place.
Research and educational discussion only — not medical advice
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist with large phase III programmes in type 2 diabetes, obesity, and cardiovascular outcomes. One of the few entries here where the evidence base is genuinely deep.
Dual GIP and GLP-1 receptor agonist
A dual incretin agonist hitting both GIP and GLP-1 receptors. Phase III results in diabetes and obesity are larger than single-agonist comparators; the mechanistic reason is still argued.
GLP-2 receptor agonist
A GLP-2 analogue approved for short bowel syndrome. A useful example of a peptide with a narrow, well-defined indication and a correspondingly narrow evidence base.
Growth hormone-releasing hormone (GHRH) analogue
A GHRH analogue approved specifically for HIV-associated lipodystrophy. Frequently cited well outside that indication, on evidence that does not extend there.
Melanocortin receptor agonist
A melanocortin agonist approved for hypoactive sexual desire disorder in premenopausal women. Approved on a real but modest effect size, which the discussion around it frequently inflates.
GLP-1 receptor agonist
The daily GLP-1 agonist that came before the weekly ones. Smaller effect, longer real-world record, and a completed cardiovascular outcomes trial.
Melanocortin-4 receptor (MC4R) agonist
An MC4R agonist approved only for a handful of rare genetic obesity syndromes. A clean example of a real drug with a genuinely tiny eligible population.
Selective melanocortin-1 receptor (MC1R) agonist
The melanocortin agonist that completed development. Approved for a rare light-sensitivity disorder, and the direct counterexample to melanotan II.
Parathyroid hormone analogue
A parathyroid hormone fragment approved for severe osteoporosis. The clearest case in this catalogue of a hormone whose effect reverses depending on how it is administered.
Decapeptide hypothalamic releasing hormone
The native GnRH decapeptide. An established diagnostic and fertility agent whose popular use, restarting suppressed testosterone production, is the use with the least evidence behind it.
Vial imagery throughout this archive is illustration. Nothing here is a product, nothing is offered for sale, and nothing on this site is intended for human use. Guides describe what the published research reports; they do not describe what anyone should do. The community rules explain how that line is enforced.